GovWire

Class 4 Medicines Defect Information: Rosemont Pharmaceuticals Limited, Mycophenolate Mofetil 1g/5ml Oral Suspension, EL(24)A/59

Medicines Healthcare Products Regulatory Agency

December 2
14:00 2024

class="gem-c-govspeak govuk-govspeak govuk-!-margin-bottom-0">

DMRC reference number

DMRC-33616486

Company name

Rosemont Pharmaceuticals Limited

Mycophenolate Mofetil 1g / 5ml Oral Suspension, PLGB 00427/0272

SNOMED Code

42314611000001100

Batch No Expiry Date Pack Size First Distributed
MYC23001 May 2025 175ml May 2024
MYC24001 Jun 2025 175ml May 2024
MYC24002 Jun 2025 175ml May 2024
MYC24003 Jun 2025 175ml Jun 2024
MYC24004 Jun 2025 175ml Jun 2024
MYC24005 Jul 2025 175ml Jun 2024
MYC24006 Jul 2025 175ml Jun 2024
MYC24007 Aug 2025 175ml Sep 2024
MYC24008 Dec 2025 175ml Not yet distributed

Active Pharmaceutical Ingredient: mycophenolate mofetil

Brief description of the problem

Rosemont Pharmaceuticals Limited has informed the MHRA that the Press-In-Bottle-Adaptor (PIBA) supplied with the batches listed above may cause the medicine to leak when attempting to withdraw a dose. Further to this, in rare instances, the seal on the PIBA can get damaged and small pieces of plastic may break off.

Advice for healthcare professional

Healthcare professionals should continue to prescribe the product, the batches listed are not being recalled. The PIBA is an aid to dispensing and the product can be administered accurately using the syringe without the PIBA.

Specific Advice for patients is included in this alert for the safe and accurate administering the product. Please provide these instructions to patients when dispensing the product.

The specific instructions in the Patient Information Leaflet (PIL) for cleaning the syringe between administration of doses should continue unchanged.

Advice for patients

If you have received one of the affected batches in the table, it is important to continue to take your medicine as prescribed by your healthcare professional. Stopping this medication suddenly can make you ill. This product is not being recalled and the following instructions below allow for the continued safe use of the product

The PIBA is the small plastic part included in the package with your medication. It is designed to fit tightly in the neck of the bottle to reduce mess when drawing up doses.

Bottles already in use

If you have already opened a bottle of the product, leave the PIBA in the bottle and continue to use as directed in the Patient Information Leaflet (PIL) that comes with your medicine. Removing the PIBA will increase the risk of damaging the plastic.

New bottles not yet opened

The PIBA helps with drawing up the correct dose of medicine but it not necessary to get an accurate dose. The product can be drawn up accurately using the syringe without the PIBA. Please follow the instructions below to get the right amount directly from the medicine bottle:

  • Discard the PIBA provided.
  • Shake the bottle well, immediately prior to use.
  • Remove the cap by pressing it down and turning anticlockwise.
  • Keeping the bottle standing upright, insert the syringe supplied into the bottle ensuring the tip of the syringe goes below the level of the liquid.
  • Fill the syringe with a small amount of medicine by pulling the piston up whilst maintaining the tip of the syringe below the level of the liquid, then push the piston down to remove any possible bubbles whilst keeping some medicine in the syringe.
  • Pull the piston upward to the graduation mark corresponding to the quantity in millilitres (ml) prescribed by your doctor.
  • Remove the syringe from the bottle.
  • Close the bottle with the plastic screw cap.
  • Empty the contents of the syringe directly into your mouth. Do not mix the medicine with any other liquid when you swallow it.
  • Immediately after use, wash the syringe as per the instructions in the PIL, using water only and leaving it to dry in the air.

If you have any concerns about the medicine you are using, please contact your healthcare professional.

Patients who experience adverse reactions or have any questions about the medication, should seek medical attention. Any suspected adverse reactions should also be reported via theMHRA Yellow Card scheme.

Further Information

For medical information enquiries please contact pharmacovigilance@rosemontpharma.com, or telephone 0113 244 1400.

For stock control enquiries please contact customerservices@rosemontpharma.com, or telephone 0113 244 1999.

Recipients of this Medicines Recall should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.

Yours faithfully

Defective Medicines Report Centre
10 South Colonnade
Canary Wharf
London
E14 4PU

Telephone +44 (0)20 3080 6574

DMRC@mhra.gov.uk

Download document

Class 4 Medicines Defect Information: Rosemont Pharmaceuticals Limited, Mycophenolate Mofetil 1g/5ml Oral Suspension, EL(24)A/59

Updates to this page

Published 2 December 2024

Share This


Enjoyed this? Why not share it with others if you've found it useful by using one of the tools below: